NL-OMON26696
Not yet recruiting
Not Applicable
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in clinical cT3-4N0M0 Melanoma
VU University medical center0 sites214 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- VU University medical center
- Enrollment
- 214
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients must be willing and able to sign the informed consent and comply with the study protocol.
- •2\.Must be ≥18 years of age.
Exclusion Criteria
- •1\.Known hypersensitivity to any oligodeoxynucleotide.
- •2\.Active autoimmune disease requiring disease\-modifying therapy at the time of screening.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 MelanomaNL-OMON52549Vrije Universiteit Medisch Centrum214
Recruiting
Not Applicable
A Randomized Controlled Phase II Clinical Trial of Reconstruction method for the Elderly patients with gastric cancer after Distal Gastrectomy; Billroth-II Versus Roux-en-Y reconstructiogastric canerJPRN-UMIN000046950Clinical Study Group of Osaka University100
Not yet recruiting
Not Applicable
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemiaACTRN12620000850976epean Blue Mountains Local Health District134
Recruiting
Phase 1
A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label ExtensioCTIS2022-502298-41-00Praxis Precision Medicines Inc.20
Active, not recruiting
Not Applicable
A Clinical Trial to Study the Safety and Effectiveness of MK-5172 with Ribavirin in Patients with Hepatitis CEUCTR2012-003340-72-ESMerck Sharp & Dohme Corp.24